Serum PRR14 and BChE expression levels in Parkinson's disease patients and their clinical significance

Abstract:Objective To investigate the expression levels and clinical significance of serum proline-rich 14(PRR14) and butyrylcholinesterase(BChE) in Parkinson's disease(PD) patients.Methods A total of 120 PD patients admitted to the Department of Neurology, Xuzhou Central Hospital, from June 2022 to June 2024 were selected as the PD group. Based on the Montreal Cognitive Assessment Scale(MoCA) scores, PD patients were divided into cognitive impairment(PD-CI, n=79) and cognitively normal(PD-NC, n=41) subgroups. Additionally, 60 healthy individuals were included as controls. Serum PRR14 levels were measured using ELISA, and BChE activity was assessed by spectrophotometry. Pearson correlation analysis was used to evaluate the relationships between PRR14, BChE, Hoehn-Yahr staging, Unified Parkinson's Disease Rating Scale-Ⅲ(UPDRS-Ⅲ) scores, and MoCA scores. Multivariate logistic regression analyzed factors influencing cognitive dysfunction in PD, and ROC curves assessed the diagnostic value of PRR14 and BChE for cognitive impairment. Results The PD group had higher serum PRR14 levels and lower BChE activity compared to controls(t/P=5.148/<0.001, 5.130/<0.001). The PD-CI subgroup exhibited longer disease duration, higher Hoehn-Yahr staging, UPDRS-Ⅲ scores, and PRR14 levels, along with lower MoCA scores and BChE activity(t/P=6.069/<0.001, 4.048/0.044, 3.055/0.003, 3.540/0.001, 4.550/<0.001, 2.631/0.010). PRR14 levels positively correlated with Hoehn-Yahr staging and UPDRS-Ⅲ scores but negatively with MoCA scores(r/P=0.345/0.038, 0.452/<0.001,-0.574/<0.001). BChE activity showed the opposite trends(r/P=-0.317/0.026,-0.469/<0.001, 0.558/<0.001). High PRR14 was an independent risk factor for cognitive dysfunction [OR=1.782(1.273-2.500)], while high BChE was protective [OR=0.643(0.478-0.863)]. The AUCs for PRR14, BChE, and their combination in diagnosing cognitive dysfunction were 0.728, 0.707, and 0.842, respectively, with the combination outperforming individual markers(Z/P=2.559/0.011, 2.883/0.004). Conclusion Elevated serum PRR14 and reduced BChE activity are closely associated with cognitive dysfunction in PD. Combined detection improves diagnostic accuracy.